Peter Attia· MD
what differs from someone taking OIC is they just have a mega high dose of glp1 all the time and what you're talking about here is as you said kind of a waxing and waning dose of glp1 that is more physiologic because it comes with your meal that's right one would not expect this type of intervention to produce the amount of weight loss you would see with carpet bombing somebody with glp1 absolutely not and and one of the other big differences is that the you know gp1s are injected so you're it's going right into the bloodstream whereas here you know it's it's a microbiome effect to your point you get the waxing and waning sort of more physiologically relevant — but it's not going to be the same as just hammering a bunch of gop1 straight into the bloodstream all the time all day all night so — yeah yeah so so again again this is so so now let's talk about the data so what was what was the first study that demonstrated that acromania could play a role in from an intervention perspective from — impact imp acting metabolism VAV blood sugar yeah some of the earliest studies are really done I mean this first of all was discovered by Dr Lee Kaplan over at MGH — and he's a bariatric surgeon and so his initial interest was you know what's what's happening to the microbiome we do the bariatric surgery and kind of came to really be one of the first people to really look at these microbes and discovered that acromania — appeared to be you know associated with or inversely associated with obesity and then started these inv vitro studies to figure out like what is it doing so you know the the work really has to go credited back to him in the early 2000s and and I want to point out one of the observations that came from his work which is a really remarkable observation which is — at least as far as the ru and Y gastric bypass which is a real organization a reorganization of the plumbing — of a person's gut that you took a person who was obese with type 2 diabetes